BCL2 and acute myeloid leukemia: Small molecules that can trigger apoptosis are widely used in research and in clinical settings, as exemplified by the BCL-2-specific BH3 mimetic venetoclax that is currently used to treat patients with acute myeloid leukaemia or chronic lymphocytic leukaemia [39].